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Intraoperative autologous transfusions have been used over
the past 20 years as a means to avoid giving patients blood
products from other individuals because of the risk of transfu-
sion-related infections such as hepatitis and HIV. The inci-
dence of hepatitis B and hepatitis C per unit of blood is
estimated at 1 in 220,000 and 1 in 1,600,000, respectively,
and the risk for HIV transmission is 1 per 1,800,000 [1].
Many patients, who for religious reasons will not accept
banked blood or autologous donated banked blood, may
accept the use of autotransfusion devices to restore their
blood volume during an operation. The use of intraoperative
autotransfusion dates back to the 19th century, when James
Blundell reported having reinfused shed blood in 10 female
patients who had hemorrhaged following childbirth.
Two broad classes of devices have been developed to facili-
tate autotransfusion, and a few examples representing each
class are listed in Table 1. One type – the red blood cell
(RBC) washing type – collects the shed blood, washes and
centrifugally separates out the RBCs, and then reinfuses
them. RBC washing devices can theoretically remove any
toxic byproducts in the scavenged blood; however, they also
remove platelets and clotting factors. The RBC washing
devices are of variable capacity and design (e.g. continuous
or discontinuous flow) and yield RBC concentrates with dif-
ferent characteristics and quality [2,3]. The second major
type of autotransfusion device – hemofiltration only devices –
just collects the blood, filters it, and reinfuses it. These
devices return all of the blood elements, including the
platelets and the clotting factors, but they do not remove
potentially harmful debris and contaminants [4].
No clinical sequelae, such as coagulopathy, renal insuffi-
ciency, abnormalities of oxygen exchange, or electrolyte dis-
orders, have been recognized with the use of either of these
devices. Devices that are capable of washing RBCs are the
most costly to set up and operate, but the presence of inflam-
matory mediators in unwashed blood and their potential to
cause unwanted pulmonary and circulatory effects may justify
the extra cost of washing RBCs before reinfusion. Economi-
cally, the set up for both types of devices has been shown to
be cost-effective only when 2 or more units are recovered
from the surgical field during the operation and then trans-
fused back into the patient.
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Abstract
Intraoperative autologous transfusions have been used for many years to avoid transmission of
infections, especially in vascular surgery, where blood usage is considerable. Several autotransfusion
devices exist, but these devices are often associated with negative outcomes such as cost,
contamination, and removal of essential blood components (e.g. platelets). Preoperative autologous
blood donation is another blood preservation method to avoid possible transfusion-related infections.
Several vascular surgery groups have compared the use of these techniques, and their results are
discussed in this review. Cell saver techniques often do not prevent the need for transfusions, nor are
they very cost-effective; therefore, their use should be considered on a case-by-case basis.
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Another method used by many surgeons is to have the
patients donate units of their own blood before their opera-
tion, thus reducing some of the risks associated with banked
blood transfusion. The use of preoperative autologous blood
donation (PAD) has been evaluated in some procedures,
including elective orthopedic procedures, coronary artery
bypass procedures, and radical prostatectomy. It was
believed that the use of PAD in these procedures would be
cost-effective, but this has not been proven to be true [5–7].
Vascular surgeons have adopted the use of intraoperative
autologous transfusions during aortic surgery in addition to
PAD [8,9]. Many vascular surgeons believed that utilization of
the cell saver devices would obviate the need to transfuse
homologous banked blood into these patients, and might be
cost-effective. A number of vascular surgery groups have
reviewed their experience with these blood administration
techniques in those patients undergoing aortic bypass or
aortic reconstruction surgery. The studies described below
are a mixture of prospective and retrospective evaluations of
cell salvage techniques, emphasizing their costs and clinical
utility in patients undergoing vascular surgery.
Kelley-Patteson and colleagues [10] reviewed four groups of
patients who were undergoing infrarenal aortic bypass to
determine the blood loss in each group and how best to
administer blood products to these patients. The groups
were as follows: group 1, abdominal aortic aneurysm repair
with a tube graft (n = 21); group 2, abdominal aortic
aneurysm repair with a bifemoral or bi-iliac bypass (n = 19);
group 3, aortofemoral bypass or bi-iliac bypass for occlusive
disease with use of the Cell Saver® Autotransfusion Device
(Haemonetics Corp., Braintree, MA, USA; n = 18); and
group 4, aortofemoral or aortoiliac bypass for occlusive
disease without use of the Cell Saver (n = 18). Groups 1 and
2 had use of the Cell Saver because it was thought that all
aneurysm patients would lose more than 2 units of blood.
Groups 3 and 4 were randomized as they presented for oper-
ation. The main purpose of the study was to identify those
patients who routinely lost less than 2 units of blood, there-
fore making routine use of the Cell Saver unnecessary.
Prospectively, the following patient data were collected [10]:
preoperative hemoglobin, estimated blood loss, Cell Saver
return volumes, intraoperative and postoperative homologous
blood transfused, postoperative hemoglobin values on the
day of surgery and on postoperative days 1 and 4, complica-
tions, and duration of hospital stay. Preoperative hemoglobin
was similar in all four groups. Surprisingly, estimated blood
loss was also similar between groups, but there was broad
variation in each group because three patients had an
extreme blood loss. In group 1, 48% of the patients had Cell
Saver return volumes of less than 500 ml. In group 2, only
16% of the patients had Cell Saver return volumes less than
500 ml. In group 3, 61% of the patients had Cell Saver
volumes returned that were less than 500 ml. Charges for the
set up of the Cell Saver Autotransfusion Device were
US$475. Set up for the cannister and suction tubing alone
was US$123.
Patients in group 2 had the greatest need for intraoperative
homologous blood administration, with nine patients (47%)
requiring blood transfusions [10]. Transfusion requirements
for the other groups were much lower, with five patients in
group 1 (24%), two patients in group 3 (11%), and three
patients in group 4 (6%) needing transfusions. Postoperative
blood transfusions were not required in group 1, and only
three patients required them in group 2. One patient each in
groups 3 and 4 required a postoperative blood transfusion.
Postoperative hemoglobin of less than 8.0 g/dl was not
reported for any patient. Costs calculated for blood transfu-
sions were US$202.75 for the first unit and US$154.25 for
each additional unit transfused.
No in-hospital deaths occurred in this series [10]. Only one
patient in group 3 had a myocardial infarction during the post-
Table 1
Examples of autotransfusion devices
Type of device Manufacturer
Hemofiltration only ConstaVac™ Blood Conservation System Stryker
Autovac™ Postoperative Orthopaedic Autotransfusion Canister Boehringer Laboratories
Solcotrans® Orthropaedic Autotransfusion System Davol
AT200™ Hemofiltration System Hematec
Red blood cell washing OrthoPAT™ Haemonetics Corp.
Continuous Autotransfusion System (CATS) Fresenius AG
Cell-Saver or Cell Saver 5 Haemonetics Corp.
Medtronic Autolog or Medtronic Sequestra 1000 Medtronic, Inc.
Cobe Baylor Rapid Autotransfusion Device (BRAT or BRAT 2) COBE CardiovascularS55
operative period. No problems with coagulopathy occurred in
any patient, and no renal or respiratory problems were noted
in any group. The duration of stay was 9.2 days for all patients
studied, with no differences seen between groups.
Kelley-Patteson and colleagues [10] concluded that routine
set up and use of the Cell Saver Autotransfusion Device is not
necessary in those patients undergoing any type of elective
aortic surgery, whether for occlusive disease or for aneurysmal
disease, because the use of homologous blood was not
altered. The only purpose that set up of the Cell Saver Auto-
transfusion Device was thought to serve in these patients was
possibly to provide the surgeon with peace of mind in the
event of sudden and unforeseen blood loss, such as when the
aorta, vena cava, or renal vein is injured.
Over a 3-year period, Ouriel and colleagues [4] studied intra-
operative autotransfusion and homologous blood transfusion
in 200 patients undergoing aortic reconstructive procedures.
A total of 100 patients had blood collected before surgery and
were reinfused with unwashed filtered shed blood during the
operation (AT group), and 100 patients were administered
homologous blood alone (HT group). Clinical, laboratory, and
economic parameters were evaluated and compared.
The groups were similar with respect to demographics, type
of procedure, baseline laboratory profiles, and comorbid con-
ditions [4]. The amount of blood salvaged and reinfused aver-
aged 1729 ± 68 ml in the AT group. Patients in the AT group
received 0.6 ± 0.1 units of homologous blood intraopera-
tively, as compared with 3.4 ± 0.1 units in the HT group
(P < 0.001). Ninety-two patients (92%) in the HT group
received 1 or more units of homologous blood during their
hospitalization, whereas only 34 (34%) of the patients in the
AT group received 1 or more units of homologous blood.
Morbidity and mortality rates were similar between groups.
Duration of stay and cost of hospitalization were similar
between groups. No abnormalities in coagulation parameters,
renal function, oxygen exchange, or electrolyte disorders
were noted in any patient. Circulating platelets were higher in
the AT group (201 ± 9 × 103/mm3 versus 157 ± 6 × 103/mm3;
P < 0.001). Fibrinogen also was higher in the AT group
(242 ± 11 mg fibrinogen/dl versus 196 ± 14 mg fibrinogen/dl;
P < 0.01). Hospital costs were compared and no overall dif-
ferences were seen. The cost of blood products and infusion
equipment was lower in the AT group, which resulted in a
cost savings of US$288 per patient (P < 0.001).
Ouriel and colleagues [4] found that the use of an autotrans-
fusion device that administers unwashed, filtered blood back
to the patients during operation was safe and efficacious,
served as an alternative to homologous blood transfusion,
and actually diminished the need for additional homologous
blood transfusions. Overall, this group of patients lost more
blood and received back more than 2 units of salvaged blood,
because two thirds of the patients operated upon had
aneurysmal disease. Those investigators felt that autologous
transfusion would be advantageous because it limits expo-
sure to homologous blood transfusions. Additionally, they
identified a small cost saving, and preservation of platelets
and fibrinogen levels in those patients receiving autotransfu-
sion during the operation. None of the patients donated
autologous units of blood preoperatively.
Goodnough and colleagues [11] conducted a retrospective
review of patients undergoing elective abdominal aortic
aneurysm repair to evaluate the cost-effectiveness of intra-
operative blood salvage techniques. Blood loss on average
was 1748 ± 1236 ml in these 184 consecutive patients,
most of whom (165) had an infrarenal repair. The mean Cell
Saver volume salvaged and reinfused was 578 ± 600 ml.
During their hospitalization, 163 patients received blood
products, with all but two receiving RBCs. A total of
128 patients received RBCs during the operation, and
77 patients received RBCs postoperatively. Thirty-two (89%)
of the 36 patients who did not receive any Cell Saver blood
required transfusions. Of those patients who had Cell Saver
blood salvaged (except for those receiving 750–999 ml of
Cell Saver blood), a similar percentage (67%) required
homologous blood transfusions. Thirty-one (63%) of the
49 patients who had less than 1000 ml estimated blood loss
had cell salvage performed, whereas 120 (87%) of
138 patients who had more than 1000 ml estimated blood
loss had cell salvage performed. The cost of cell salvage in
this series was US$326 ± 73. Cost savings could only be
demonstrated in 22% of the patients who underwent surgery
that employed cell salvage techniques.
Those investigators concluded that intraoperative cell salvage
was most beneficial for those patients who have intraopera-
tive blood losses of 1000 ml or more and Cell Saver volumes
infused of 750 ml or more [11]. These findings are similar to
those in knee replacement surgery, hip replacement surgery,
and spinal fusion operations.
Huber and colleagues [12] reviewed the medical records of all
patients undergoing elective abdominal aortic reconstructions
at Shands Hospital at the University of Florida College of Med-
icine between January 1991 and June 1995. A total of
173 cases were identified and five were excluded (three
because complete medical records were not available, and
two because massive coagulopathic bleeding occurred during
the postoperative period). The Cell Saver Autotransfusion
Device was used in 138 of the 168 procedures reviewed.
Estimated blood loss was 1737 ± 1299 ml and the mean
volume of blood salvaged by the Cell Saver was
702 ± 644 ml [12]. Estimated blood loss and Cell Saver
salvage rates were higher in those patients with aneurysms
than in those patients with aortoiliac occlusive disease (esti-
mated blood loss of 2127 ± 1467 ml versus
1415 ± 1047 ml; 927 ± 790 ml versus 515 ± 408 ml Cell
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Saver volume returned). Cell Saver blood salvage amounts
were 500 ml or greater in 79.4% of aneurysm patients and in
52% of patients with aortoiliac occlusive disease. Predictors
of 500 ml Cell Saver salvage returns or greater were as
follows: large aneurysms (6.79 ± 1.84 cm versus
5.72 ± 0.71 cm) and male sex (82.0% versus 46.2%) in
patients with aneurysms; and lower preoperative platelet
counts (262 ± 93 × 103/mm3 versus 311 ± 113 × 103/mm3),
concomitant renal revascularization (20.5% versus 0%), and
prolonged operative time (7.9 ± 2.4 hours versus
6.9 ± 2.1 hours) in those patients with aortoiliac occlusive
disease. Cell salvage returns of 1250 ml or more were rela-
tively uncommon (28.6% in patients with aneurysms versus
5.3% in those with aortoiliac occlusive disease), and predic-
tors were seen only in those patients with aneurysms and
included those patients with concomitant vascular proce-
dures (38.8% versus 15.6%) and those patients who
required suprarenal clamping (27.8% versus 6.7%).
Even though Cell Saver was used, 73.8% of patients
required homologous blood transfusions, with a mean of
3.0 ± 3.1 units being transfused during the hospital stay [12].
No difference was seen in the blood transfusion requirement
between patients with aneurysms and those with aortoiliac
occlusive disease. The calculated cost for cell salvage return
of 1 unit (determined by dividing the cost of the cell salvage
set up by the number of units actually salvaged) was
US$128.77 for patients with aneurysms and US$231.91 for
patients with aortoiliac occlusive disease. A potential saving if
the cell salvage technique was not used was also calculated:
US$252.80 for patients with aneurysms and US$352.84 for
those with aortoiliac occlusive disease.
Huber and coworkers [12] concluded that the use of cell
salvage techniques is not cost-effective during elective aortic
reconstruction procedures and should only be used for
complex procedures in which considerable blood loss is
anticipated. None of the other clinical factors could accu-
rately predict the high volume of blood loss that could be sal-
vaged during the procedure in order to make use of the Cell
Saver cost-effective.
That group went on to report an additional study of the use of
intraoperative autologous transfusion devices with a decision
analysis model [13]. The authors took the transfusion require-
ments from the previously cited study from either homologous
blood transfusions or cell salvage techniques, and then fac-
tored in the risk for allogeneic transfusion-related complica-
tions (transfusion reaction, hepatitis B, hepatitis C, HIV,
human T-cell lymphotropic virus type I and II), along with
associated treatment costs (US$ and quality-adjusted life
years [QALYs]). The use of the Cell Saver proved not to be
cost-effective in either abdominal aneurysm repair or aorto-
iliac occlusive disease patients. The cost was increased by
US$263.75 in the aneurysm patients, but only 0.00218
QALYs were added (US$120 794 per QALY). For aortoiliac
occlusive disease the cost was US$356.68 and 0.00062
QALYs were added (US$528 275 per QALY). Cost-effec-
tiveness was achieved only if the incidence of hepatitis C was
10-fold higher and if blood loss routinely was more than
5 units in the aneurysm patients and 6 units in the aortoiliac
occlusive disease patients.
Conclusion
The use of cell salvage techniques in vascular surgery has the
potential to prevent the use of homologous blood transfu-
sions, but in reality that does not appear to occur. The risk for
transmission of disease by blood transfusions is sufficiently
low that the use of the Cell Saver does not appear to have an
impact on the individual patient. Cost savings only occur
when there is a high blood loss and a high RBC salvage rate.
If the surgeon is concerned, the reservoir is the optimal
method to use in cases that have the potential for high blood
loss, and if excessive blood loss does occur then the cell
salvage device can be activated.
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